Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 37(1): 7-18, 2019 01.
Article
in En
| MEDLINE
| ID: mdl-29951793
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrazoles
/
Pyrimidines
/
Technology Assessment, Biomedical
/
Waldenstrom Macroglobulinemia
/
Models, Economic
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Health_economic_evaluation
/
Health_technology_assessment
Aspects:
Patient_preference
Limits:
Adult
/
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Pharmacoeconomics
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2019
Document type:
Article
Affiliation country:
United kingdom
Country of publication:
New Zealand